

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/813,340	03/20/2001	Hiep Huatan	PC10381A	1232	
75	90 06/18/2002			•	
Paul H. Ginsburg Pfizer Inc 20th Floor 235 East 42nd Street New York, NY 10017-5755			EXAMINER		
			EVANS, CHARESSE L		
			ART UNIT	PAPER NUMBER	
,			1615		
			DATE MAILED: 06/18/2002	DATE MAILED: 06/18/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/813,340	HUATAN ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Charesse L. Evans	1615				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE M - Extens after S - If the p - If NO p - Failure - Any re	PRTENED STATUTORY PERIOD FOR REPLY IAILING DATE OF THIS COMMUNICATION. The communication of time may be available under the provisions of 37 CFR 1.13 by (6) MONTHS from the mailing date of this communication. The communication of the commu	86(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on 20 M	March 2001					
2a)□	<u> </u>	is action is non-final.					
3)							
Dispositio	on of Claims						
4)🛛 (Claim(s) $\frac{1-11}{2}$ is/are pending in the application	•	·				
4	a) Of the above claim(s) is/are withdraw	vn from consideration.					
5)□(5) Claim(s) is/are allowed.						
6)⊠ (6)⊠ Claim(s) <u>1-11</u> is/are rejected.						
7) 🗌 (Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
ا لــا(۱۱	If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
	a) All b) Some * c) None of:						
,	1.⊠ Certified copies of the priority document:	s have been received.					
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* S	* See the attached detailed Office action for a list of the certified copies not received.						
14)□ Ad	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)						
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s) 4	5) Notice of Informal I	/ (PTO-413) Paper No(s) Patent Application (PTO-152)				
			1814				

DETAILED ACTION

Claims 1-11 are pending in this Action.

Priority

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in the United Kingdom on March 23, 2000. It is noted, however, that applicant has not filed a certified copy of the United Kingdom application as required by 35 U.S.C. 119(b).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary.

Applicant is advised of the obligation under 37 CFR 1.56 to point out the

inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ebert et al (US 4,428,927). The claims are directed to a formulation comprised of a solid masticable portion and one or more reservoir portions encompassed by the masticable portion.

Ebert teaches a chewable, filled one-piece soft elastic gelatin capsule (Abstract). The referenced gelatin capsule comprises about 10-90% by weight gelatin, and taste modifiers (column 2, lines 54-61 and column 5, Examples II and III). The fill may be selected from a variety of materials, including antacids, cough and cold preparation, sore throat remedies, antiseptics, dental preparations and breath fresheners (Abstract).

While the reference is silent regarding the Young's modulus of the solid masticable portion, differences in physical descriptions will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such physical characteristic is critical. In this case, what is the criticality of applicant's claimed value? Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum

or workable ranges by routine experimentation. *In re Aller*, 220 F.2d 454, 105 USPQ 233, 235 (CCPA 1955).

One of ordinary skill in the art would be motivated to modify the teachings of Ebert with the expectation of creating a chewable product that is broadly applicable to both human and non-human use. The chewable product would deliver consistent streams of medicament to the user of the chewable product.

Conclusion

No claims are allowed at this time

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charesse L. Evans whose telephone number is 703-308-6400. The examiner can normally be reached on Monday-Thursday 7:00a - 4:30p; Alternating Fridays 7:00a - 3:30p.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

cle June 14, 2002

THURMAN R. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600